Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Other Non Operating Income (2016 - 2025)

Cardiff Oncology's Other Non Operating Income history spans 15 years, with the latest figure at -$1000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 50.0% year-over-year to -$1000.0; the TTM value through Dec 2025 reached $5000.0, up 112.82%, while the annual FY2025 figure was $5000.0, 112.82% up from the prior year.
  • Other Non Operating Income for Q4 2025 was -$1000.0 at Cardiff Oncology, roughly flat from -$1000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $268000.0 in Q3 2021 and bottomed at -$383000.0 in Q4 2022.
  • The 5-year median for Other Non Operating Income is -$1000.0 (2025), against an average of -$3277.8.
  • The largest annual shift saw Other Non Operating Income soared 7000.0% in 2021 before it plummeted 7760.0% in 2022.
  • A 5-year view of Other Non Operating Income shows it stood at $5000.0 in 2021, then tumbled by 7760.0% to -$383000.0 in 2022, then skyrocketed by 96.61% to -$13000.0 in 2023, then surged by 84.62% to -$2000.0 in 2024, then soared by 50.0% to -$1000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Other Non Operating Income are -$1000.0 (Q4 2025), -$1000.0 (Q2 2025), and $7000.0 (Q1 2025).